메뉴 건너뛰기




Volumn 22, Issue 4, 2016, Pages 915-922

Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; COMPLEMENTARY DNA; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; OSIMERTINIB; DNA;

EID: 84964224932     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1627-T     Document Type: Article
Times cited : (205)

References (26)
  • 1
    • 84875937242 scopus 로고    scopus 로고
    • Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies
    • Li T, Kung HJ, Mack PC, Gandara DR.Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
    • (2013) J Clin Oncol , vol.31 , pp. 1039-1049
    • Li, T.1    Kung, H.J.2    Mack, P.C.3    Gandara, D.R.4
  • 2
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Jänne, P.A.2    Lee, J.C.3    Tracy, S.4    Greulich, H.5    Gabriel, S.6
  • 4
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3    Jouary, T.4    Gutzmer, R.5    Millward, M.6
  • 6
    • 84926028427 scopus 로고    scopus 로고
    • Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): A multicenter, open-label, phase II trial (BRF113928)
    • Planchard D, Kim T, Maziéres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928). Ann Oncol 2014;25 (Supplement 5): v1-v41.
    • (2014) Ann Oncol , vol.25 , pp. v1-v41
    • Planchard, D.1    Kim, T.2    Maziéres, J.3    Quoix, E.4    Riely, G.5    Barlesi, F.6
  • 8
    • 84865833740 scopus 로고    scopus 로고
    • High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing
    • Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
    • (2012) Cancer Discov , vol.2 , pp. 82-93
    • Wagle, N.1    Berger, M.F.2    Davis, M.J.3    Blumenstiel, B.4    Defelice, M.5    Pochanard, P.6
  • 11
    • 84936132730 scopus 로고    scopus 로고
    • Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-ofconcept study from BioCAST/IFCT-1002
    • Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-ofconcept study from BioCAST/IFCT-1002. Clin Cancer Res 2014;20: 4613-24.
    • (2014) Clin Cancer Res , vol.20 , pp. 4613-4624
    • Couraud, S.1    Vaca-Paniagua, F.2    Villar, S.3    Oliver, J.4    Schuster, T.5    Blanché, H.6
  • 12
    • 84655167222 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer
    • Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115-21.
    • (2012) J Thorac Oncol , vol.7 , pp. 115-121
    • Goto, K.1    Ichinose, Y.2    Ohe, Y.3    Yamamoto, N.4    Negoro, S.5    Nishio, K.6
  • 13
    • 79960975050 scopus 로고    scopus 로고
    • Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
    • Lee YJ, Yoon KA, Han JY, Kim HT, Yun T, Lee GK, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011;17:5179-87.
    • (2011) Clin Cancer Res , vol.17 , pp. 5179-5187
    • Lee, Y.J.1    Yoon, K.A.2    Han, J.Y.3    Kim, H.T.4    Yun, T.5    Lee, G.K.6
  • 14
    • 84906250256 scopus 로고    scopus 로고
    • Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumorDNAas a surrogate for determination of EGFR status
    • Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumorDNAas a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
    • (2014) J Thorac Oncol , vol.9 , pp. 1345-1353
    • Douillard, J.Y.1    Ostoros, G.2    Cobo, M.3    Ciuleanu, T.4    Cole, R.5    McWalter, G.6
  • 15
    • 84861746437 scopus 로고    scopus 로고
    • Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA
    • Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
    • (2012) Sci Transl Med , vol.4 , pp. 136ra68
    • Forshew, T.1    Murtaza, M.2    Parkinson, C.3    Gale, D.4    Tsui, D.W.5    Kaper, F.6
  • 16
    • 84896539307 scopus 로고    scopus 로고
    • Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
    • Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
    • (2014) Clin Cancer Res , vol.20 , pp. 1698-1705
    • Oxnard, G.R.1    Paweletz, C.P.2    Kuang, Y.3    Mach, S.L.4    O'Connell, A.5    Messineo, M.M.6
  • 18
    • 84903218109 scopus 로고    scopus 로고
    • An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
    • Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
    • (2014) Nat Med , vol.20 , pp. 548-554
    • Newman, A.M.1    Bratman, S.V.2    To, J.3    Wynne, J.F.4    Eclov, N.C.5    Modlin, L.A.6
  • 21
    • 84930755018 scopus 로고    scopus 로고
    • Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M
    • Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M. Nat Med 2015.
    • (2015) Nat Med
    • Thress, K.S.1    Paweletz, C.P.2    Felip, E.3    Cho, B.C.4    Stetson, D.5    Dougherty, B.6
  • 22
    • 84938196408 scopus 로고    scopus 로고
    • The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
    • Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015;21:3924-33.
    • (2015) Clin Cancer Res , vol.21 , pp. 3924-3933
    • Niederst, M.J.1    Hu, H.2    Mulvey, H.E.3    Lockerman, E.L.4    Garcia, A.R.5    Piotrowska, Z.6
  • 23
    • 84987849616 scopus 로고    scopus 로고
    • Acquired resistance of EGFR-mutant lung cancer to a T790M-Specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain
    • Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-Specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015.
    • (2015) JAMA Oncol
    • Yu, H.A.1    Tian, S.K.2    Drilon, A.E.3    Borsu, L.4    Riely, G.J.5    Arcila, M.E.6
  • 24
    • 84923059431 scopus 로고    scopus 로고
    • Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis
    • Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 2014;4:6269.
    • (2014) Sci Rep , vol.4 , pp. 6269
    • Luo, J.1    Shen, L.2    Zheng, D.3
  • 25
    • 84907855592 scopus 로고    scopus 로고
    • Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
    • de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
    • (2014) Science , vol.346 , pp. 251-256
    • De Bruin, E.C.1    McGranahan, N.2    Mitter, R.3    Salm, M.4    Wedge, D.C.5    Yates, L.6
  • 26
    • 84907808265 scopus 로고    scopus 로고
    • Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
    • Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
    • (2014) Science , vol.346 , pp. 256-259
    • Zhang, J.1    Fujimoto, J.2    Wedge, D.C.3    Song, X.4    Seth, S.5    Chow, C.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.